KDR and neoplasm: The findings suggest that the Hsp90 inhibitor AT-533 inhibits tumor angiogenesis by inhibiting breast cancer growth and blocking HIF-1α/VEGF/VEGFR-2-mediated signaling, thereby, triggering an antitumor response in breast cancer [171].